The project commenced after the biology team at the DDU screened one of their collections of compounds against the malaria parasite, healthcanal.com reported.
Over a span of 18 months, two such compounds were refined through cycles of compound design, chemical synthesis and biological testing.
MMV chief scientific officer Tim Wells said Malaria control has been a cause for concern and the current effective treatment, artemisinin is developing resistance.
"In preparation for this eventuality MMV and partners are researching over 50 projects in the largest-ever pipeline of antimalarial medicines," Wells added.
The University’s Drug Discovery Unit has the remit of developing translational research at Dundee and outside.
MMV, a Swiss-based foundation, is recognized as a product development partnership (PDP) in the field of antimalarial drug research and development.